MaxCyte, Inc.
1.5100-0.04 (-2.58%)
Oct 29, 4:00:02 PM EDT · NasdaqGS · MXCT · USD
Key Stats
Market Cap
160.98MP/E (TTM)
-Basic EPS (TTM)
-0.42Dividend Yield
0%Recent Filings
8-K
CCO Soleymannezhad departs MaxCyte
MaxCyte's Chief Commercial Officer Ali Soleymannezhad departed on August 11, 2025, triggering a nine-month severance payout of his base salary and COBRA contributions, contingent on signing a release. This exit removes key commercial leadership amid the biotech's push for cell therapy partnerships. No interim replacement disclosed. The change risks short-term sales momentum.
8-K
MaxCyte Q2 revenue dips
MaxCyte reported Q2 2025 total revenue of $8.5 million, down 18% from last year, yet core revenue climbed 8% to $8.2 million amid customer pipeline shifts. SPL program revenue plunged 89% to $0.3 million due to milestone timing, while the company added two new SPL clients, Adicet Bio and Anocca AB, lifting total agreements to 31. Cash stood at $165.2 million after $7 million in SeQure Dx acquisition costs. It lowered 2025 guidance to flat-to-10% core revenue decline and $5 million in SPL revenue, but eyes profitability with existing funds. Headwinds sting short-term.
10-Q
Q2 FY2025 results
MaxCyte's Q2 revenue dipped 18% y/y to $8.5M, driven by a sharp 89% drop in non-core SPL program-related revenue to $0.3M, yet core revenue from instruments and PAs climbed 8% y/y to $8.2M, signaling steady demand for cell engineering tools. Gross margin held firm at 82%, down slightly from 86% amid the mix shift, while operating loss widened to $14.2M from $12.0M on higher R&D spend for tech advancements. The $2.3M SeQure acquisition in January added $0.3M quarterly revenue and bolstered assay services, recognizing $3.7M goodwill and $0.7M intangibles amortized over 7-15 years. Cash and equivalents stood at $15.2M with $149.9M in investments, no debt, and operating cash burn of $24.3M YTD. Customer concentration persists as a key risk.
8-K
MaxCyte delists from AIM
MaxCyte announced on June 25, 2025, its application to delist common stock from the London Stock Exchange's AIM market, effective June 26, 2025, ending trading there after that date. Nasdaq listing under MXCT remains unaffected. This streamlines operations while preserving U.S. market access. No financial impacts disclosed.
8-K
Equity plan shares increased
MaxCyte's stockholders approved an amendment to its 2022 Equity Incentive Plan at the June 18, 2025 annual meeting, adding 2,950,000 shares to the reserve for employee and director incentives. This boosts the total pool to over 13 million shares, enhancing talent retention amid biotech competition. All proposals passed decisively. Yet dilution looms for existing holders.
BLFS
BioLife Solutions, Inc.
27.54-0.44
CTKB
Cytek Biosciences, Inc.
4.01-0.19
CTSO
Cytosorbents Corporation
0.78-0.05
IART
Integra LifeSciences Holdings C
15.43-0.13
LAB
Standard BioTools Inc.
1.19-0.08
MASS
908 Devices Inc.
7.69-0.30
MDNC
MEDINOTEC INC
5.00+0.00
MDT
Medtronic plc.
91.73-1.50
PLSE
Pulse Biosciences, Inc
17.11-0.24
RCEL
Avita Medical, Inc.
3.69+0.03